$23.82 Million in Sales Expected for CareDx Inc (CDNA) This Quarter

Share on StockTwits

Analysts expect CareDx Inc (NASDAQ:CDNA) to post $23.82 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for CareDx’s earnings, with estimates ranging from $22.87 million to $25.00 million. CareDx reported sales of $14.05 million in the same quarter last year, which would suggest a positive year over year growth rate of 69.5%. The business is scheduled to report its next earnings results on Thursday, May 9th.

On average, analysts expect that CareDx will report full year sales of $106.14 million for the current financial year, with estimates ranging from $105.90 million to $106.52 million. For the next financial year, analysts expect that the firm will report sales of $155.59 million, with estimates ranging from $144.94 million to $164.83 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover CareDx.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, March 6th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). CareDx had a negative net margin of 61.06% and a negative return on equity of 63.64%. The company had revenue of $23.51 million for the quarter, compared to the consensus estimate of $23.34 million.

Several equities research analysts have recently issued reports on CDNA shares. HC Wainwright set a $30.00 price target on CareDx and gave the company a “hold” rating in a research report on Thursday, March 7th. Zacks Investment Research raised CareDx from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 7th. BidaskClub raised CareDx from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 25th. Finally, Jefferies Financial Group started coverage on CareDx in a research report on Friday, February 15th. They issued a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the stock. CareDx presently has an average rating of “Buy” and a consensus target price of $34.00.

In other news, Director Michael Goldberg sold 50,000 shares of CareDx stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $37.36, for a total value of $1,868,000.00. Following the completion of the transaction, the director now owns 84,740 shares in the company, valued at $3,165,886.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sasha King sold 2,500 shares of CareDx stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $25.00, for a total transaction of $62,500.00. Following the completion of the transaction, the insider now owns 76,387 shares of the company’s stock, valued at approximately $1,909,675. The disclosure for this sale can be found here. Insiders sold 185,822 shares of company stock valued at $5,815,664 in the last quarter. 3.40% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CareDx in the 4th quarter worth approximately $45,000. First Interstate Bank bought a new position in CareDx in the 4th quarter worth approximately $80,000. Great West Life Assurance Co. Can bought a new position in CareDx in the 4th quarter worth approximately $81,000. Meeder Asset Management Inc. bought a new position in CareDx in the 3rd quarter worth approximately $124,000. Finally, Legal & General Group Plc raised its position in CareDx by 19.5% in the 4th quarter. Legal & General Group Plc now owns 6,129 shares of the company’s stock worth $154,000 after purchasing an additional 998 shares during the last quarter. Hedge funds and other institutional investors own 86.86% of the company’s stock.

NASDAQ CDNA traded up $0.64 during trading on Wednesday, hitting $37.00. 450,683 shares of the company traded hands, compared to its average volume of 820,209. CareDx has a 12 month low of $5.73 and a 12 month high of $38.38. The firm has a market cap of $1.50 billion, a P/E ratio of -28.24 and a beta of 1.21.

About CareDx

CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients.

Recommended Story: Fiduciary

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts’ Weekly Ratings Updates for RPM International
Analysts’ Weekly Ratings Updates for RPM International
Crypto Harbor Exchange  One Day Trading Volume Tops $2,607.00
Crypto Harbor Exchange One Day Trading Volume Tops $2,607.00
Analysts Anticipate Hoegh LNG Partners LP  to Announce $0.35 EPS
Analysts Anticipate Hoegh LNG Partners LP to Announce $0.35 EPS
VeriME Market Cap Tops $374,353.00
VeriME Market Cap Tops $374,353.00
Molina Healthcare, Inc.  Receives Average Rating of “Hold” from Analysts
Molina Healthcare, Inc. Receives Average Rating of “Hold” from Analysts
SPINDLE  Reaches Market Capitalization of $2.12 Million
SPINDLE Reaches Market Capitalization of $2.12 Million


 
© 2006-2019 Zolmax.